Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01315379
Other study ID # 6166
Secondary ID
Status Recruiting
Phase N/A
First received March 3, 2011
Last updated October 9, 2016
Start date April 2011
Est. completion date March 2017

Study information

Verified date October 2016
Source Rabin Medical Center
Contact Maayan Shorer, PhD
Phone ++97239253864
Email maayans@clalit.org.il
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine whether Prolonged Exposure Therapy (PE)is effective in the treatment of post-traumatic stress symptoms in children and adolescents with mild traumatic brain injury (m-TBI) due to motor vehicle accident.


Description:

Motor vehicle accidents account for a majority of TBI cases and are a leading cause for Post Traumatic Stress Disorder (PTSD) among children. The vast majority of these cases involve mild TBI (mTBI) with persistent post concussion syndromes. However, the empirical data on treatment in this field is scarce. Few studies demonstrated that cognitive behavioral therapies can be effective for adults with mild TBI suffering from Acute Stress Disorder, but no research, to date, addressed this question in pediatric population. In the current research we intend to examine the effectiveness of PE in reducing post-traumatic stress symptoms in children and adolescents with m-TBI caused by motor vehicle accident, in comparison to children and adolescents without brain injury.

Sixty children age 6 to 18 attending the Anxiety clinic in Schneider Children's Medical Center of Israel will be included. All subjects will be treated with a manualized 12-18 week Prolonged Exposure protocol. Participants will undergo assessments, which will include interviews, questionnaires and neuropsychological tests concerning symptoms of PTSD, emotional and cognitive functioning. Ratings and neuropsychological testing will be made at baseline and following completion of treatment. Follow up will include questionnaires ratings at 2 weeks, 4 weeks and 12 weeks after completion of treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender Both
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria:

For the whole sample:

- Children age 6 to 18

- Language spoken: Hebrew, Arabic

- DSM- IV R diagnosis: PTSD

- Car accident event within past 3 years

For the m-TBI group:

- Any of the following symptoms or experiences occurring during or shortly after the accident: loss of consciousness, dazed, confused, saw stars, headache, dizziness, irritability, memory gap (not remembering injury or injury period), visual loss, abdominal pain].

- Diagnosis of MTBI within 3 years as confirmed by CT/MRI/fMRI.

- Glasgow coma scale; GCS<15.

Exclusion Criteria:

- Children presenting with psychotic symptoms

- Children presenting with mental retardation

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Intervention

Behavioral:
Prolonged Exposure Therapy
This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.

Locations

Country Name City State
Israel Schneider Children's Medical Center of Israel Petach Tikva

Sponsors (1)

Lead Sponsor Collaborator
Rabin Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of participants with PTSD diagnosis as a measure of recovery rates Psychological evaluation using the Hebrew translation of the Childhood version of the Schedule for Affective Disorders and Schizophrenia (Apter et al., 1989). After up to 18 weeks of PE treatment No
Secondary Change from Baseline in Neuropsychological Functioning at Treatment Completion Subjects will take paper and pencil and computer tests to evaluate memory, learning, attention and concentration, vocabulary and naming.
The neuropsychological testing battery includes: Raven's Progressive Matrices, BRIEF, WISC-III-Hebrew Version (Digit Span), CMS (Spatial Span), D-KEFS (Design Fluency, Sorting Test, Trails Making Test), CPT, Stroop,TOMM Effort validity test, The Connors Rating Scale- Revised Long version
After up to 18 weeks of treatment No
Secondary Change from Baseline in The Child PTSD Symptoms Scale at Treatment Completion The Child PTSD Symptoms Scale (Foa et al., 2001) At up to 18 weeks of PE treatment No
Secondary Change from Baseline in The Child PTSD Symptoms Scale at 2 weeks Follow Up The Child PTSD Symptoms Scale (Foa et al., 2001) 2 weeks following treatment completion No
Secondary Change from Baseline in The Child PTSD Symptoms Scale at 4 weeks Follow Up The Child PTSD Symptoms Scale (Foa et al., 2001) 4 weeks following treatment Completion No
Secondary Change from Baseline in The Child PTSD Symptoms Scale at 12 weeks Follow Up The Child PTSD Symptoms Scale (Foa et al., 2001) 12 weeks following treatment completion No
Secondary Change from Baseline in the Childrens Depression Inventory at Treatment Completion Childrens Depression Inventory, Kovacs, 1992 After up to 18 weeks of PE treatment No
Secondary Change from Baseline in the Children's Global Assessment Scale at Treatment Completion After up to 18 weeks of PE treatment No
Secondary Change from Baseline in The State-Trait Anxiety Inventory for Children at Treatment Completion The State-Trait Anxiety Inventory for Children, Spielberger et al. After up to 18 weeks of PE Treatment No
Secondary Change from Baseline in The Well-Being Questionnaire at Treatment Completion WHO-5 (Bech, 1998) After up to 18 weeks of PE treatment No
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1